Published in

Elsevier, The Lancet, 10168(393), p. 229-240, 2019

DOI: 10.1016/s0140-6736(18)32984-2

Links

Tools

Export citation

Search in Google Scholar

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Journal article published in 2019 by Owen A. O'Connor, Steven Horwitz, Su-Peng Yeh, Nancy L. Bartlett, Jacob Haaber Christensen, Sam Yuen, Eva Domingo-Domenech, Pier Luigi Zinzani, Barbara Pro, Won Seog Kim, Tatyana Feldman, Anne Lennard, Tim Illidge ORCID, David Belada, Árpád Illés and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO